EP3873601A4 - METHODS AND COMPOSITIONS FOR THE PREVENTION OF TYPE 1 DIABETES - Google Patents

METHODS AND COMPOSITIONS FOR THE PREVENTION OF TYPE 1 DIABETES Download PDF

Info

Publication number
EP3873601A4
EP3873601A4 EP20804811.6A EP20804811A EP3873601A4 EP 3873601 A4 EP3873601 A4 EP 3873601A4 EP 20804811 A EP20804811 A EP 20804811A EP 3873601 A4 EP3873601 A4 EP 3873601A4
Authority
EP
European Patent Office
Prior art keywords
diabetes
prevention
compositions
methods
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20804811.6A
Other languages
German (de)
French (fr)
Other versions
EP3873601A1 (en
Inventor
Francisco Leon
Kevan C. Herold
Jay S. Skyler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Provention Bio Inc
Original Assignee
Provention Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provention Bio Inc filed Critical Provention Bio Inc
Priority claimed from PCT/US2020/032891 external-priority patent/WO2020232247A1/en
Publication of EP3873601A1 publication Critical patent/EP3873601A1/en
Publication of EP3873601A4 publication Critical patent/EP3873601A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
EP20804811.6A 2019-05-14 2020-05-14 METHODS AND COMPOSITIONS FOR THE PREVENTION OF TYPE 1 DIABETES Pending EP3873601A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962847466P 2019-05-14 2019-05-14
PCT/US2020/032891 WO2020232247A1 (en) 2019-05-14 2020-05-14 Methods and compositions for preventing type 1 diabetes

Publications (2)

Publication Number Publication Date
EP3873601A1 EP3873601A1 (en) 2021-09-08
EP3873601A4 true EP3873601A4 (en) 2022-03-23

Family

ID=75926572

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20804811.6A Pending EP3873601A4 (en) 2019-05-14 2020-05-14 METHODS AND COMPOSITIONS FOR THE PREVENTION OF TYPE 1 DIABETES

Country Status (2)

Country Link
EP (1) EP3873601A4 (en)
CN (2) CN112839707A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007147090A2 (en) * 2006-06-14 2007-12-21 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
WO2015073833A1 (en) * 2013-11-15 2015-05-21 Pharmacyclics, Inc. Methods for delaying or preventing the onset of type 1 diabetes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2904586A1 (en) * 2013-03-08 2014-09-12 The Curators Of The University Of Missouri Methods and compositions for the treatment and/or prevention of type 1 diabetes
ES3038990T3 (en) * 2017-09-08 2025-10-16 Diamyd Medical Ab Genotype stratification in diabetes treatment and prevention

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007147090A2 (en) * 2006-06-14 2007-12-21 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
WO2015073833A1 (en) * 2013-11-15 2015-05-21 Pharmacyclics, Inc. Methods for delaying or preventing the onset of type 1 diabetes

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Anti-CD3 Prevention ANTI-CD3 MAB (TEPLIZUMAB) FOR PREVENTION OF DIABETES IN RELATIVES AT-RISK FOR TYPE 1 DIABETES MELLITUS (Protocol TN-10)", TYPE 1 DIABETES TRIALNET, 25 June 2014 (2014-06-25), XP055889308, Retrieved from the Internet <URL:https://clinicaltrials.gov/ProvidedDocs/61/NCT01030861/Prot_000.pdf> [retrieved on 20220209] *
JANELLE A NOBLE ET AL: "Genetics of the HLA Region in the Prediction of Type 1 Diabetes", CURRENT DIABETES REPORTS, CURRENT SCIENCE INC, NEW YORK, vol. 11, no. 6, 13 September 2011 (2011-09-13), pages 533 - 542, XP019971883, ISSN: 1539-0829, DOI: 10.1007/S11892-011-0223-X *
KEVAN C. HEROLD ET AL: "An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 381, no. 7, 15 August 2019 (2019-08-15), US, pages 603 - 613, XP055760445, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1902226 *
LONG ET AL.: "Partial exhaustion of CD 8 T cells and clinical response to teplizumab in new-onset type 1 diabetes", SCIENCE IMMUNOLOGY, vol. 1, no. 5, 18 November 2016 (2016-11-18), XP055760444 *
MANNERING S I ET AL: "The case for an autoimmune aetiology of type 1 diabetes", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 183, no. 1, 21 October 2015 (2015-10-21), pages 8 - 15, XP071082897, ISSN: 0009-9104, DOI: 10.1111/CEI.12699 *
See also references of WO2020232247A1 *
WHERRETT DIANE K. ET AL: "Prevention of Type 1 Diabetes", ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA., vol. 38, no. 4, 1 December 2009 (2009-12-01), PHILADELPHIA, pages 777 - 790, XP055889301, ISSN: 0889-8529, DOI: 10.1016/j.ecl.2009.08.006 *
WU YAN-LING ET AL: "Risk Factors and Primary Prevention Trials for Type 1 Diabetes", INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, vol. 9, no. 7, 18 July 2013 (2013-07-18), pages 666 - 679, XP055889302, ISSN: 1449-2288, DOI: 10.7150/ijbs.6610 *

Also Published As

Publication number Publication date
CN112839707A (en) 2021-05-25
EP3873601A1 (en) 2021-09-08
CN119236066A (en) 2025-01-03

Similar Documents

Publication Publication Date Title
EP3874030A4 (en) COMPOSITIONS AND METHODS FOR ENGINEERING T LYMPHOCYTES
MA55082A (en) COMPOSITIONS, METHODS, AND KITS FOR THE ADMINISTRATION OF POLYRIBONUCLEOTIDES
EP3894343A4 (en) METHODS AND COMPOSITIONS FOR THE ADMINISTRATION OF CARBON DIOXIDE
MA53445A (en) METHODS AND COMPOSITIONS FOR THE MODIFICATION OF PLANTS
EP3924478A4 (en) COMPOSITIONS AND METHODS FOR TREATING GLYCOGENOSIS TYPE 1A
EP3612215A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY INFLAMMATION
EP3635100A4 (en) COMPOSITIONS AND METHODS FOR EXPRESSING OTOFERLINE
MA53391A (en) COMPOSITIONS FOR AGRICULTURE AND RELATED PROCESSES
EP3793562A4 (en) METHODS AND COMPOSITIONS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
EP3893655A4 (en) METHODS FOR THE PREPARATION OF A VEGETABLE PROTEIN COMPOSITION
EP4009778A4 (en) METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ECTOMYCORHIZAL MYCELIUMS AND METHODS OF USE THEREOF
MA45688A (en) COMPOSITIONS AND METHODS FOR THE POTENTIALIZATION OF ANTIMICROBIAL AGENTS
EP3803403A4 (en) IMAGING COMPOSITIONS AND METHODS
EP3801534A4 (en) COMPOSITIONS AND METHODS FOR INCREASE TETRAHYDROBIOPTERINE PLASMA EXPOSURE
EP3735457A4 (en) COMPOSITIONS AND METHODS FOR PRODUCING MEGACARYOCYTES
EP3810109A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING CD73
EP3990920A4 (en) METHODS AND COMPOSITIONS FOR PROXIMITY LIGATURE
MA52961A (en) COMPOSITIONS AND METHODS FOR THE REDUCTION OR TREATMENT OF INFLAMMATION
EP3980774A4 (en) COMPOSITIONS AND METHODS FOR DETECTING AUTOANTIBODIES
EP3788070A4 (en) HEMOGLOBIN PRODUCTION COMPOSITIONS AND METHODS
EP4058035A4 (en) IMMUNOTHERAPY COMPOSITIONS AND METHODS
EP3638277A4 (en) COMPOSITIONS AND METHODS FOR INHIBITION OF BETA-SECRETASE
MA49651A (en) COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH IMPRESSION DEFECTS
EP3803416A4 (en) COMPOSITIONS AND METHODS FOR DETECTING TRAUMATIC BRAIN INJURY
MA55531A (en) METHODS FOR THE TREATMENT OF BETA-THALASSEMIA

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210603

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

A4 Supplementary search report drawn up and despatched

Effective date: 20220217

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 5/50 20060101ALI20220215BHEP

Ipc: A61K 38/28 20060101ALI20220215BHEP

Ipc: A61P 5/48 20060101AFI20220215BHEP

17Q First examination report despatched

Effective date: 20220304

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)